Last week, we noted that an essay in Slate suggested the relationship between medical journals and advertisers can be, well, a bit gamey. And so there was a proposal that journals start disclosing the revenue received from a company whose drug or device is discussed, and provide details about the number of ad pages or the amount spent to purchase reprints and supplements. There was also the suggestion that professional societies sponsoring journals should disclose dealings with manufacturers.

The idea isn’t new, but the issue remains important, and controversial. And so we asked you whether medical journals should disclose financial relationships with drugmakers? A majority made clear that disclosure is preferable. A caveat: this isn’t a scientific poll. But temperature readings can be useful. Journal editors and publishers, take note.

Yes - 57 votes, or 85 percent;
No - 10 votes, or 15 percent.